In vitro characterization of solrikitug, a differentiated anti-TSLP antibody, provides distinct epitope binding profile and superior potency compared to tezepelumab
We are actively expanding our immunology and inflammation pipeline, with a laser focus on therapeutics for indications with limited or no available treatments.
